- Advertising
- Asia
- Bangladesh
- Biological Inventions
- BRAND VALUATION
- China
- Comparative Advertisement
- Copyright
- Copyright Infringement
- Copyright Litigation
- Counterfeiting
- Covid
- Data Protection
- Design
- Digital Marketing Rights
- DRM
- Electronics
- Geographical Indication
- India
- Indian Patents Act
- Indonesia
- Intellectual Property
- Interim Injunction
- IP Commercialization
- IP Licensing
- IP Litigation
- IP Practice in India
- IPAB
- IPAB Decisions
- Japan
- Legal Issues
- Licensing
- Malaysia
- Myanmar
- NCLT
- NEPAL
- Net Neutrality
- News & Updates
- Office
- Patent Commercialisation
- Patent Cooperation Treaty
- patent infringement
- Patent Licensing
- Patent Litigation
- Patent Opposition
- Patent Prosecution
- Patent Rule Amendment
- Patent Term Extension
- Patents
- pharma
- Philippines
- Punitive Damages
- Section 3(D)
- section 64
- Singapore
- South-east Asia
- Technology
- Technology Transfer
- Thailand
- Trademark
- Trademark Litigation
- UAE
- Uncategorized
- USPTO
- Vietnam
- WIPO
Not only to this, Pfizer have decided for not receiving any royalties on sales in low-income countries and even waiving royalties for countries which are covered under agreement which are almost 95 low- and middle-income countries. Such factors will remain as Covid-19 remains classified as a Public Health Emergency of International Concern by the World Health Organization.
"We believe the MPP model represents an efficient way to work within the current innovation ecosystem to hopefully achieve broader and faster access, particularly for small molecules, where the MPP model has already been proven successful," Pfizer spokesperson said.
Author: Saransh Chaturvedi (Advocate, LLM (IIT Kharagpur)-an associate at IIPRD, in case of any queries please contact/write back to us via email saransh@iiprd.com